Chemed Q4 2024 revenue up 9.2% to $640M; adj. EPS $6.83; guides FY2025 adj. EPS $24.95-$25.45

CHEMED CORP

2024-FY EPS reported $19.89 revenue$2,431,287,000

GAAP diluted EPS $6.02 (+2.0% YoY); adjusted diluted EPS $6.83 (+3.5% YoY).
VITAS net patient revenue $411M (+17.4% YoY); ADC 22,179 (+14.6%).
Roto-Rooter revenue $229M (-2.9% YoY); adjusted EBITDA margin 26.3% (-120 bps).
FY2025 guidance: VITAS revenue growth 10.5%-11.3%, Roto-Rooter revenue growth 2.4%-3.0%.
No debt; $178.4M cash; repurchased 388,235 shares for $212.8M at $548.13/share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.